{
  "docId": "019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "docSlug": "714b2223d61a474cc0c3d011e3fc18ab",
  "documentTitle": "Centessa | IPO Presentation Deck | 33 slides",
  "authorId": "centessa",
  "authorName": "Centessa Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 24,
  "pageCount": 33,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a split-layout comparing internal development status against external competitive programs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-ff46-75e9-a6a2-27d0e899d3b8/24",
  "deckHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "deckJsonHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8.json",
  "deckAnchorHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "Status & Upcoming Milestones: Phase 1 study ongoing, details on dosing, tolerability, PK, and recruitment status for Part B.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "500d9075-52f9-484c-8028-5fab0e02215e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "list",
      "text": "Competitive Landscape: VX-864, ARO-AAT, Belcesiran, ALN-AAT02 with their respective development phases and sponsors.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce2786ff-36c0-4a85-ad34-ae2e7cfc4585",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "Mid-to-late 2021: Data from 28-day repeat dosing study in PiXZ subjects (Phase 1, Part B)",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7cd5b2d-357b-44d3-9ff2-645440c8b76e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.87
      },
      "kind": "list",
      "text": "Mid-to-late 2021: US IND Filing",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea3b30e2-44c9-4680-be0f-a2060c76a014",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "ZF874: Status and Competition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87d97196-269a-4e41-b97c-185ebbff2502",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}